慢性丙型肝炎治疗方案的研究进展

干扰素联合利巴韦林是治疗丙型肝炎公认有效的治疗方案。该方案可以抑制体内丙型肝炎病毒(hepatitis C virus,HCV)的复制,减轻对肝脏的损害,改善肝功能。在维持持续病毒学应答(sustained virological response,SVR)以及阻止病情进展方面发挥了重要作用,通过动态检测慢性丙型肝炎(chronic hepatitis C,CHC)患者行干扰素和利巴韦林治疗前后的各项指标(包括患者临床症状、一般体检、血常规、生化指标、HCV-RNA转阴率、HCV病毒载量等),探讨天冬氨酸转氨酶与淋巴细胞比值指数(ALRI)与各项指标的关联性,特别是对HCV病毒载量、病毒应答及复发等疗效的预测价值,旨在为CHC的临床治疗提供一种简单、快速、廉价、客观的疗效评价新指标。为临床预防和个性化精准治疗CHC从分子生物学角度提供实用的方法。

Progress in research on treatment plan for chronic hepatitis C

Interferon combined with ribavirin is a recognized and effective treatment for hepatitis C.The program can inhibit the replication of hepatitis C virus(HCV)in the body,reduce damage to the liver,and improve liver function.It plays an important role in maintaining sustained virological response(SVR)and preventing disease progression by dynamically detecting the indicators including clinical symptoms,general physical examination,blood routine,biochemical indicators,HCV-RNA negative rate,HCV viral load,etc.of chronic hepatitis C(CHC)patients before and after treatment with interferon and ribavirin,to explore the association between aspartate aminotransferase to lymphocyte ratio index(ALRI)and the various indicators.In particular,it has predictive value for HCV viral load,viral response and recurrence,and is intended to provide a simple,rapid,inexpensive and objective evaluation of clinical efficacy for CHC clinical treatment.